Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

Franco LocatelliMichael B JordanCarl AllenSimone CesaroCarmelo RizzariAnupama RaoBarbara DegarTimothy P GarringtonJulian SevillaMaria-Caterina PuttiFranca FagioliMartina AhlmannJose-Luis Dapena DiazMichael HenryFabrizio De BenedettiAlexei GromGenevieve LapeyrePhilippe JacqminMaria BallabioCristina de Min

Published in: The New England journal of medicine (2020)

Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. (Funded by NovImmune and the European Commission; NI-0501-04 and NI-0501-05 ClinicalTrials.gov numbers, NCT01818492 and NCT02069899.).

Keyphrases

young adults
metal organic framework
transition metal
cancer therapy
drug delivery